IDEAYA Biosciences, a biotechnology company, has recently seen a range of analyst ratings. These ratings provide insights into how analysts perceive the company’s stock and can influence investor sentiment. Let’s take a closer look at these ratings and what they mean for IDEAYA Biosciences.
Over the last quarter, IDEAYA Biosciences has been evaluated by a total of eight analysts. Among these analysts, two have given bullish ratings, six have given somewhat bullish ratings, and none have given indifferent, somewhat bearish, or bearish ratings. This suggests that the majority of analysts have a positive outlook on IDEAYA Biosciences.
To understand how these ratings have evolved over time, we can examine the data from the last 30 days, one month ago, two months ago, and three months ago. In the last 30 days, there have been no bullish ratings, one somewhat bullish rating, and no indifferent, somewhat bearish, or bearish ratings. One month ago, there was one bullish rating, two somewhat bullish ratings, and no indifferent, somewhat bearish, or bearish ratings. Two months ago, there were no bullish ratings, two somewhat bullish ratings, and no indifferent, somewhat bearish, or bearish ratings. Three months ago, there was one bullish rating, one somewhat bullish rating, and no indifferent, somewhat bearish, or bearish ratings.
Based on the data provided by eight analysts offering 12-month price targets, the average price target for IDEAYA Biosciences is $39.88. The highest price target is $44.00, while the lowest price target is $32.00. This indicates a positive sentiment among analysts regarding the future performance of IDEAYA Biosciences.
It is worth noting that the current average price target has increased by 7.2% from the previous average price target of $37.20. This suggests that analysts have become more optimistic about IDEAYA Biosciences’ prospects in the short term.
Investors interested in staying updated on IDEAYA Biosciences analyst ratings can visit the Benzinga Insights website for the latest information. Analyst ratings provide valuable insights into market sentiments and can help investors make informed decisions regarding their investments.
It is important to remember that analysts are not infallible and their ratings are subject to error. They base their assessments on various factors such as company financial statements, industry trends, and interactions with company insiders. However, unexpected events or changes in market conditions can impact the accuracy of their predictions.
In conclusion, the analyst ratings for IDEAYA Biosciences indicate a predominantly positive sentiment among analysts. The average price target has increased, suggesting growing optimism about the company’s future performance. Investors should consider these ratings alongside their own research and risk assessment when making investment decisions.
